Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases

Abstract

Aim: Several genomic signatures are available to predict Prostate Cancer (CaP) outcomes based on gene expression in prostate tissue. However, no signature was tailored to predict aggressive CaP in younger men. We attempted to develop a gene signature to predict the development of metastatic CaP in young men.

Methods: We measured genome-wide gene expression for 119 tumor and matched benign tissues from prostatectomies of men diagnosed at ≤ 50 years and > 70 years and identified age-related differentially expressed genes (DEGs) for tissue type and Gleason score. Age-related DEGs were selected using the improved Prediction Analysis of Microarray method (iPAM) to construct and validate a classifier to predict metastasis using gene expression data from 1,232 prostatectomies. Accuracy in predicting early metastasis was quantified by the area under the curve (AUC) of receiver operating characteristic (ROC), and abundance of immune cells in the tissue microenvironment was estimated using gene expression data.

Results: Thirty-six age-related DEGs were selected for the iPAM classifier. The AUC of five-year survival ROC for the iPAM classifier was 0.87 (95%CI: 0.78-0.94) in young (≤ 55 years), 0.82 (95%CI: 0.76-0.88) in middle-aged (56-70 years), and 0.69 (95%CI: 0.55-0.69) in old (> 70 years) patients. Metastasis-associated immune responses in the tumor microenvironment were more pronounced in young and middle-aged patients than in old ones, potentially explaining the difference in accuracy of prediction among the groups.

Conclusion: We developed a genomic classifier with high precision to predict early metastasis for younger CaP patients and identified age-related differences in immune response to metastasis development.

Keywords

Differentially expressed gene / immune cell enrichment / metastasis / prostate cancer / tissue microenvironment / age / prediction / patient stratification / clinical phenotype

References

[1] Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Bethesda, MD. 2019, https://seer.cancer.gov/csr/1975_2017/, November 2019 SEER data submission(posted to the SEER web site, April 2020.

[2] LiJ,KingJ.Recent trends in prostate cancer testing and incidence among men under age of 50..Cancer Epidemiol2012;36:122-7

[3] BleyerA,BarrR.Prostate cancer in young men: An emerging young adult and older adolescent challenge..Cancer2020;126:46-57

[4] KuceraR,TopolcanO.Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions..EPMA J2020;11:399-418 PMCID:PMC7429585

[5] KinnearNJ,PlagakisS.Prostate cancer in men aged less than 50 years at diagnosis..World J Urol2016;34:1533-9

[6] MahalAR,FrancoI.Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database..Cancer2019;125:3338-46

[7] Bill-AxelsonA,GarmoH.Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up..N Engl J Med2018;379:2319-29

[8] BoströmPJ,CattoJW.Genomic Predictors of Outcome in Prostate Cancer..Eur Urol2015;68:1033-44

[9] DingY,WardenC.Gene Expression Differences in Prostate Cancers between Young and Old Men..PLoS Genet2016;12:e1006477 PMCID:PMC5189936

[10] SalinasCA,Ishak-HowardM.Prostate cancer in young men: an important clinical entity..Nat Rev Urol2014;11:317-23 PMCID:PMC4191828

[11] SteurerS,AdamM.TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer..Eur Urol2014;66:978-81

[12] WeischenfeldtJ,FeuerbachL.Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer..Cancer Cell2013;23:159-70

[13] ZhaoSG,KothariV.High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer..Prostate Cancer Prostatic Dis2015;18:229-36 PMCID:PMC4579590

[14] SmythGK,ScottHS.Use of within-array replicate spots for assessing differential expression in microarray experiments..Bioinformatics2005;21:2067-75

[15] ErhoN,VergaraIA.Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy..PLoS One2013;8:e66855 PMCID:PMC3691249

[16] TibshiraniR,NarasimhanB.Diagnosis of multiple cancer types by shrunken centroids of gene expression..Proc Natl Acad Sci U S A2002;99:6567-72 PMCID:PMC124443

[17] WangS.Improved centroids estimation for the nearest shrunken centroid classifier..Bioinformatics2007;23:972-9

[18] BlagusR.Improved shrunken centroid classifiers for high-dimensional class-imbalanced data..BMC Bioinformatics2013;14:64 PMCID:PMC3687811

[19] KarnesRJ,DavicioniE.Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population..J Urol2013;190:2047-53 PMCID:PMC4097302

[20] KleinEA,HaddadZ.A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy..Eur Urol2015;67:778-86

[21] DenRB,ShowalterTN.Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy..Int J Radiat Oncol Biol Phys2014;89:1038-46 PMCID:PMC4432840

[22] AranD,ButteAJ.xCell: digitally portraying the tissue cellular heterogeneity landscape..Genome Biol2017;18:220 PMCID:PMC5688663

[23] WilcoxR.Introduction to Robust Estimation and Hypothesis Testing.2016;4th edAcademic press

[24] JegerlehnerS,AujeskyD.Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?.PLoS One2019;14:e0210434 PMCID:PMC6361620

[25] LoebS,NicholsonJ.Overdiagnosis and overtreatment of prostate cancer..Eur Urol2014;65:1046-55 PMCID:PMC4113338

[26] KleinEA,Magi-GalluzziC.A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling..Eur Urol2014;66:550-60

[27] CuzickJ,FisherG.Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study..The Lancet Oncology2011;12:245-55 PMCID:PMC3091030

[28] MurphyLC,ParkesA.Altered expression of estrogen receptor coregulators during human breast tumorigenesis..Cancer Res2000;60:6266-71

[29] KhoAT,CaiZ.Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers..Genes Dev2004;18:629-40 PMCID:PMC387239

[30] HumphreyPA.Gleason grading and prognostic factors in carcinoma of the prostate..Mod Pathol2004;17:292-306

[31] SprattDE,DeheshiS.Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease..J Clin Oncol2017;35:1991-8 PMCID:PMC6530581